What question did this study set out to answer?

The aim is to assess how therapy assurance resolves misclassification of ventricular fibrillation in ICDs.

January 10, 2026Journal of Arrhythmia0 citationsOpen Access

A Case of VF Misclassification Corrected by VF Therapy Assurance: Implications for ICD Programming

NMNaoki MATSUMOTOOsaka City General Hospital KSKenji Shimeno MMMasanori MatsuoOsaka City General Hospital

Key Result

Ventricular fibrillation therapy assurance (VFTA) enabled successful resuscitation by promptly delivering shocks after initial shock failure in low-amplitude VF.

Key Points

The aim is to assess how therapy assurance resolves misclassification of ventricular fibrillation in ICDs.
Utilized ventricular fibrillation therapy assurance to detect persistent VF after shock failure.
Assessed the effectiveness of VFTA in enabling timely shock delivery.
Monitored device programming changes to prevent misclassification.
VFTA successfully identified VF that initial shocks failed to treat.
Timely shock delivery led to successful resuscitation following VF misclassification.
Optimized device programming minimized future treatment delays in life-threatening arrhythmias.

Structured PICO

Does Ventricular Fibrillation Therapy Assurance (VFTA) prevent misclassification and treatment delay of ventricular fibrillation with low-amplitude signals in patients with implantable cardioverter-defibrillators?

Population

1 58-year-old female with a family history of sudden cardiac death, diagnosed with idiopathic ventricular fibrillation (VF) during malignant lymphoma treatment, who underwent implantation of an implantable cardioverter-defibrillator (ICD) for secondary prevention.

Intervention

Ventricular Fibrillation Therapy Assurance (VFTA) algorithm activated on an implantable cardioverter-defibrillator

Outcome

Detection of persistent VF after initial shock failure and successful resuscitation

Ventricular fibrillation therapy assurance (VFTA) can correct VF misclassification caused by low-amplitude signals, preventing life-threatening treatment delays in ICD patients.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

Implantable cardioverter-defibrillator undersensing may delay therapy in ventricular fibrillation with low-amplitude signals. Ventricular fibrillation therapy assurance (VFTA) detected persistent VF after initial shock failure, enabling timely shock delivery and successful resuscitation. VFTA may help optimize device programming by preventing misclassification and treatment delay in life-threatening arrhythmias.

Ask AI

Helpful

Bookmark

View Full Paper